BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark restated a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd.

BIOLASE Price Performance

BIOL stock opened at $0.01 on Wednesday. The company’s 50-day moving average is $0.01 and its 200-day moving average is $0.04. The stock has a market capitalization of $314,025.80, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.